News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Laura Cortesi

Articles by Laura Cortesi

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByBOLDSCIENCE,Pedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

Trending on CancerNetwork

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Leveraging Novel Software to Further Improve Personalized Cancer Care

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

© 2025 MJH Life Sciences^®

All rights reserved.